A new treatment combining ReCET and semaglutide could eliminate the need for insulin in type 2 diabetes

Scientists have discovered that a new combination of ReCET (Reversible Electroporation Cellular Therapy) and semaglutide can significantly reduce the need for insulin in patients with type 2 diabetes. A recent study showed that 86% of participants who received this treatment no longer required insulin to control their blood glucose levels.

ReCET is a technique that uses electric pulses to temporarily alter cell membranes, allowing for improved cellular function without destroying the cells. In the context of type 2 diabetes, this technology appears to restore the body’s ability to better process glucose, reducing the need for exogenous insulin. Semaglutide, on the other hand, is a GLP-1 receptor agonist already used in diabetes treatment. It helps regulate glucose levels by stimulating insulin secretion and reducing glucose production in the liver.

The study results were remarkable, as the combination of both treatments allowed the majority of patients to achieve adequate glucose control without needing insulin, an important breakthrough in disease management. This represents a significant advantage, especially for patients who rely on multiple daily insulin injections.

Moreover, the treatment was safe and well-tolerated by the participants. No serious side effects were reported, and mild effects, such as discomfort at the electroporation site, were temporary. These findings create excitement about the potential for this therapy to become a viable option for many people with type 2 diabetes.

Despite the promising results, researchers emphasize the need for further clinical trials to validate these findings in a larger population and over a longer period. Upcoming studies will seek to confirm whether the observed improvement is sustained in the long term and if the combination of ReCET and semaglutide can become a standard treatment.

In conclusion, this new therapeutic combination offers hope for reducing insulin dependence in type 2 diabetes, a change that could transform the management of this chronic disease.